Rebound Phenomenon after Nirmatrelvir/Ritonavir Treatment of Coronavirus Disease-2019 in High-Risk Persons

Authors :: Nischal, Ranganath
John C, O'Horo
Douglas W, Challener
Sidna M, Tulledge-Scheitel
Marsha L, Pike
R, Michael O'Brien
Raymund R, Razonable
Aditya, Shah
Source :: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
Publication Year :: 2022
Abstract: In a cohort of 483 high-risk patients treated with nirmatrelvir/ritonavir for coronavirus disease-2019, two patients (0.4%) required hospitalization by day 30. Four patients (0.8%) experienced rebound of symptoms, which were generally mild, at median of 9 days after treatment, and all resolved without additional COVID-19-directed therapy.

ISSN :: 15376591
Database :: OpenAIRE
Journal :: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Accession number :: edsair.pmid..........0bb76889bb877e4eb3b253c8e9c52d85

Tools